According to an analysis by Triton Market Research, the CRISPR market in North America will surge at a CAGR of 23.85% in the forthcoming years between 2019 and 2028.
The countries evaluated in the North American CRISPR market are:
• Canada
• The United States
In the United States, the high occurrence of diseases has gained the traction of pharmaceutical firms to develop advanced medicines and vaccines. These companies are developing pharmaceutical proteins, such as antibodies in genetically modified plants. For example, rice has been modified with alpha-antitrypsin protein production in them. This protein is used in the treatment of hemorrhages and liver disease.
In 2017, the US was successful in editing the DNA of a viable human embryo using CRISPR, a gene-editing tool under the leadership of Shoukhrat Mitalipov of Oregon Health and Science University. The team effectively corrected a gene mutation, causing a heart condition called hypertrophic cardiomyopathy. This ability to edit a human DNA is considered as a first step towards the prevention of the birth of babies with incurable diseases. These developments in the US is anticipated to boost the CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats) market in the coming years.
The massive government fundings towards the promotion of the research activities in Canda is likely to be the critical factor for the growth of the CRISPR market. The Canadian government invested in research activities in the field of drug discovery, genomics and stem cell research. Also, it offered about $237.2 million in order to support the activities of Genome Canada. These initiatives indicate the growth of the CRISPR market in Canada.
Established in 1951, Sigma-Aldrich (Merck KGaA) is a US-based life science and technology company. In November 2015, Sigma-Aldrich was acquired entirely by Merck KGaA. Sigma-Aldrich provides its products to research & applied labs and industrial & commercial markets. They are also used in scientific research, including genomic and proteomic research, the diagnosis of disease and biotechnology & pharmaceutical development. The company has its headquarters in St. Louis, Missouri, the US.
Some of the key companies in the CRISPR market are Intellia Therapeutics Inc, Cellectis, Sigma-Aldrich (Merck KGaA), GenScript, New England Biolabs, GeneCopoeia Inc, Origene Technologies Inc, Addgene, Horizon Discovery Ltd, Applied StemCell, Thermo Fisher Scientific Inc, Editas Medicine, DiaCarta, Caribou Biosciences Inc, Sangamo Therapeutics, Transposagen Bio (Hera BioLabs), Genedata AG, Precision Biosciences, Lonza, Integrated DNA Technologies Inc and CRISPR Therapeutics.